Description

Citicoline (CDP-Choline) Nootropic Powder

 

 

 

 

 

 

 

 

 

 

 

CAS Number	987-78-0
Other Names	CDP-Choline, 987-78-0, Citicholine, Cytidine 5′-Diphosphocholine, Citidoline, Cyscholin, Cytidoline, Difosfocin, cyticholine
IUPAC Name	[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(trimethylazaniumyl)ethyl phosphate
Molecular Formula	C₁₄H₂₇N₄O₁₁P₂⁺
Molecular Weight	489.33
Purity	≥99% Pure (LC-MS)
Liquid Availability	N/A
Powder Availability	25 grams
Gel Availability	N/A
Storage	Store in cool dry environment, away from direct sunlight.
Terms	All products are for laboratory developmental research USE ONLY. Products are not for human consumption.

 

Citicoline is a naturally occurring nootropic compound that has been shown to improve brain health and cognition. The compound increases levels of two major neurotransmitters, dopamine and acetylcholine. Acetylcholine is associated with memory and learning processes while dopamine is known to boost overall mood. That being said, various animal-based studies have emphasized how treatment with citicoline can help increase neuroprotective effects and overall cognition, as well as treating depression, Parkinson’s Disease, and addiction.

Administration of citicoline has been shown to decrease levels of glutamate in the brain while increasing choline stores and adenosine triphosphate (ATP) to be used for other biological pathways in the body. By decreasing glutamate and increasing ATP, the compound protects against ischemic neurotoxicity. Animal studies have examined the additional antioxidant and anti-inflammatory effects of citicoline in cases of brain, renal, and hepatic injuries.

In addition to the anti-inflammatory and antioxidant effects of the nootropic, evidence has found that citicoline has the ability to reverse cognitive impairments and enhance learning. Researchers suspect these effects stem from the accelerated resynthesis of phospholipids and the resulting protection of the cell membrane. Furthermore, the neuroprotective effects were highlighted in an animal-based study where 10 mg/kg of citicoline was administered following the induction of cardiac arrest. In the group administered the nootropic, results determined that disability scores, seizure frequency, and mortality rate were all drastically reduced, indicating that citicoline has neuroprotective effects.

In relation to the improvement of cognition, recent experimentation has compared citicoline to the drug Levodopa; a drug commonly used to treat Parkinson’s Disease. 7 different animal based studies, including 335 test subjects, were conducted comparing the two treatments with all subjects exhibiting various degrees of severity. Overall, the results of the studies found that there were more benefits when administering citicoline in addition to Levodopa. citicoline by itself also led to an improvement of symptoms that were not seen with Levodopa alone.

Another interesting benefit of citicoline is the role it plays in substance addiction. Three different studies took place that initially induced methamphetamine, cocaine, and alcohol dependency on different animals. Varying doses of citicoline, ranging from 500-2000 mg, were administered over a trial period of 8-12 weeks and compared to a placebo group. The results of these studies found that citicoline led to a decrease in cravings for the different substances, and higher dosages led to a higher aversion to the substance. However, there was inconclusive data as to whether or not administration of the nootropic actually led to decreased consumption despite less cravings (https://www.drugs.com/npp/citicoline.html#20505289).

Due to its neuroprotective effects and ability to improve cognition, further studies have reported that citicoline also has the potential to act as an effective form of treatment following a stroke. 14 different animal models which included a total of 522 subjects were cited describing how citicoline affects infarct volume and neurological deficits associated with a stroke. The meta-analysis of the studies found that infarct volume was reduced by a mean amount of 27.4% (ranging from 19.9% to 35.6 %). In regards to neurological deficits, citicoline led to a mean improvement of 20.2% (ranging from 6.8% to 33.7%).

Results also found that citicoline more efficiently reduced infarct volume in cases of proximal occlusions rather than distal occlusions. Furthermore, the data indicated that the compound has a cumulative effect as multiple doses were far more effective than a single dose. Overall, the researchers were able to conclude that citicoline proves to be an effective treatment for stroke while also optimizing neuroprotection (https://pubmed.ncbi.nlm.nih.gov/22845688/).

The findings of the previous study are supported by the work of researchers Clark et. Al, who examined whether citicoline works as an acute stroke treatment. The researchers hypothesized that these benefits of the compound could be due to the protective and regenerative effects that citicoline has on the cellular membrane. As it was previously mentioned, citicoline accelerates the resynthesis of phospholipids leading to the stabilization of cellular membranes, release of free fatty acids, and reduced generation of free radicals.

This mechanism of action has led to worldwide conduction of animal-based studies in cases of ischemic and hemorrhagic stroke. Results have determined that citicoline reduces size of the infarct in both ischemic and hemorrhagic models. Administration of citicoline up to 24 hours following a moderate to severe stroke increases the probability of a full recovery at 3 months post-stroke (https://pubmed.ncbi.nlm.nih.gov/19351232/).

The nootropics sold by Umbrella Labs are sold for laboratory research only. The description above is not medical advice and is for informative purposes only.

Citicoline (CDP-Choline) is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

 

 

File Name	View/Download
08-04-2023-Umbrella-Labs-Citicoline-Certificate-Of-Analysis-COA.pdf

 

VIEW CERTIFICATES OF ANALYSIS (COA)